



# Redeye initiates commissioned research on FluoGuide

**Copenhagen, Denmark, 12 October 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) has entered into an agreement with the Swedish investment bank Redeye AB (Redeye) on commissioned research coverage.**

Starting today, Redeye has initiated its commissioned research, meaning that Redeye will continuously monitor and analyze FluoGuide’s operations, its products, markets, and competitors.

The initial research report is available [here](#)

**For further information, please contact:**

Morten Albrechtsen, CEO  
FluoGuide A/S  
+45 24 25 62 66  
[ma@fluoguide.com](mailto:ma@fluoguide.com)

**Certified Adviser:**

Svensk Kapitalmarknadsgransking AB  
Phone: +46 70 755 95 51  
E-mail: [ca@skmg.se](mailto:ca@skmg.se)

**About FluoGuide**

FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is conducting a proof-of-concept clinical study (phase I/II) to demonstrate the effect of FG001 in patients with high grade glioma. FluoGuide is listed on Nasdaq First North Sweden under the ticker “FLUO”.